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http://dx.doi.org/10.1016/j.stemcr.2016.12.012SUMMARYSubtype-specific human cardiomyocytes (CMs) are valuable for basic and applied research. Induction of cardiomyogenesis and enrich-
ment of nodal-like CMs was described for mouse pluripotent stem cells (mPSCs) in response to 1-ethyl-2-benzimidazolinone (EBIO), a
chemical modulator of small-/intermediate-conductance Ca2+-activated potassium channels (SKs 1–4). Investigating EBIO in human
pluripotent stem cells (PSCs), we have applied three independent differentiation protocols of low to high cardiomyogenic efficiency.
Equivalent to mPSCs, timed EBIO supplementation during hPSC differentiation resulted in dose-dependent enrichment of up to 80%
CMs, including an increase in nodal- and atrial-like phenotypes. However, our study revealed extensive EBIO-triggered cell loss favoring
cardiac progenitor preservation and, subsequently, CMswith shortened actionpotentials. Proliferative cells were generallymore sensitive
to EBIO, presumably via an SK-independent mechanism. Together, EBIO did not promote cardiogenic differentiation of PSCs, opposing
previous findings, but triggered lineage-selective survival at a cardiac progenitor stage, whichwe propose as a pharmacological strategy to
modulate CM subtype composition.INTRODUCTION
Cardiomyocytes (CMs) from human pluripotent stem cells
(hPSCs), including human embryonic stem cells (hESCs)
and induced pluripotent stem cells (hiPSCs), possess a
high potential to regenerate diseased hearts. They also pro-
vide a human cell source formore predictive drug discovery
and safety platforms (Braam et al., 2010; Kempf et al.,
2016).
Aiming at chemically defined conditions, we and others
have improved cardiac differentiation by supplementing
synthetic effectors such as the p38 MAPK inhibitor
SB203580 (Graichen et al., 2008; Kempf et al., 2011) and
WNT pathway inhibitors (Willems et al., 2011). Based on
thiswork, recent progress demonstrated efficient induction
of CMs by tightly controlling the temporal pattern ofWNT
pathway activity using chemical compounds (Lian et al.,
2012), which subsequently enabled upscaling of CMgener-
ation directly from hPSC in suspension culture using in-
strumented, stirred tank bioreactors (Kempf et al., 2014,
2015; Kropp et al., 2016).
Another key requirement remains the targeted genera-
tion of specific CM subtypes. Successful differentiation
into ventricular-, atrial-, or pacemaker-like CM subtypes
was mainly investigated using mouse PSCs, but translationStem Cell Re
This is an open access article under the Cto human cells remains a challenge (Birket et al., 2015;
David and Franz, 2012).
Supplementation of the compound 1-ethyl-2-benzimi-
dazolinone (EBIO), an established modulator of small-
and intermediate-conductance Ca2+-activated potassium
channels (SKs), was described to induce the differentiation
into highly pure CM populations from mouse ESCs. Inter-
estingly, this was accompanied by the significant enrich-
ment of pacemaker-like CMs (Kleger et al., 2010).
Small (SK1–3) and intermediate (IK or SK4) conductance
channels are gated solely by [Ca2+]i and exert hyperpolariz-
ing effects that influence the activity of excitable and non-
excitable cells (Kohler et al., 1996). Once activated, all SK
channels can be kept in an open conformation by the pro-
totype compound EBIO, causing a leftward shift in the
Ca2+-activation curves of SKs and thereby reducing the
rate of deactivation upon Ca2+ removal (Devor et al.,
1996; Hougaard et al., 2007). SKs regulate a wide range of
physiological properties. However, their role(s) in develop-
mental biology is not well understood, although differen-
tial expression of SKs in the cardiovascular system has
been described (Tuteja et al., 2005).
Intrigued by the findings of Kleger et al. (2010) in mouse
cells, we have investigated the effect of EBIO on human
PSCs. We show that tightly controlled supplementationports j Vol. 8 j 305–317 j February 14, 2017 j ª 2016 The Author(s). 305
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of EBIO during differentiation indeed results in high hPSC-
CM purity, including a shift toward cell phenotypes with
shorter duration of action potential (AP). In contrast to
the proposed mechanism in mouse PSCs, our work high-
lights that CM subtype enrichment is not mediated
by directing lineage-specific differentiation but rather by
lineage-selective survival at the cardiac progenitor stage,
demonstrating a pharmacological strategy for lineage
purification.RESULTS
CM Enrichment by EBIO Is Concentration and Time
Dependent
HES3 cells were differentiated as embryoid bodies (EBs) in
chemically defined conditions (bSF protocol; Xu et al.,
2008) and supplemented with 1 mM EBIO (Kleger et al.,
2010) or solvent controls (DMSO). Addition of EBIO from
day 0 or day 3 onward led to almost entire cell loss and aber-
rant EBs lacking any contractility (Figure S1A). Treatment
starting on days 4–8 allowed the formation of EBs that var-
ied in size and microscopic appearance of beating foci and,
strikingly, significantly reduced cell counts were observed
in response to EBIO treatment compared with controls
(Figure S1B). Quantification of cardiac troponin T (cTnT)
and a-actinin staining revealed substantial CM enrichment
of 60% versus 5%–10% in controls when initiating
EBIO supplementation on day 6 (Figure 1A). CM enrich-
ment was confirmed by increased gene expression levels
of cTnT (TNNT2), myosin heavy chain 6 (MYH6), myosin
light chain 2a (MLC2a; MYL7), and hyperpolarization-acti-
vated cation channel 4 (HCN4) (Figures S1C–S1F), whereas
expression of the ventricular myocyte marker MYL2
(MLC2v) was reduced (Figure S1G). Only treatment at
0.75–1 mM EBIO resulted in increased CM purity (Figures
1B, 1C, and S1I) but reduced cell yields (Figure 1B) andFigure 1. Timed Treatment with 1 mM EBIO Results in 9-Fold Enr
(A) Quantification of CM purity based on cTnT staining for timepoi
mean ± SEM).
(B and C) EBIO concentration-dependent enrichment: total cell and
ferentiation (C) (n = 3 independent experiments; mean ± SEM).
(D) Schematic outline of the EBIO-based, bSF differentiation protoco
(E) Immunofluorescence analysis of replated control (left panel) and
NKX2.5 (scale bars, 200 mm) showing typical cross-striations (far-rig
(F and G) Quantification of CMs at endpoint day 16 (n = 5 independent
and (G) respective absolute cell numbers (n = 4 from three independ
(H) qRT-PCR for TNNT2 (n = 3), MYH6, MLC2a, TBX3, MLC2v, and HCN
(I and J) Dissociated/replated cells stained for smooth muscle actin
(J; n = 2 biological repeats; mean ± SEM).
(K) qRT-PCR for the endothelial marker PECAM1 (CD31; n = 4 independ
(OCT4; n = 6 independent experiments; n = 1 for hESC; mean ± SEM).
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.was accompanied by typical changes in EB morphology
(Figure S1H; Movies S1 and S2).
In summary, 1 mM EBIO supplementation for 10 days
starting on day 6 was most efficient in CM enrichment
and was therefore applied in further experiments.
Optimized EBIO Treatment Leads to 9-Fold CM
Enrichment
Endpoint analysis of EB-derived cells (Movie S3) revealed
typical cross-striations of a-actinin/NKX2.5 double-posi-
tive cells, suggesting bona fide CM formation (Figure 1E)
and significant 9-fold enrichment from 7.7% ± 1.7% to
68.7% ± 8.8% cTnT+ cells, on average (Figure 1F). Impor-
tantly, we noted that the EBIO treatment was not only
accompanied by an overall cell loss but also by 80%
reduced CM counts compared with controls (Figure 1G).
A significant increase in expression of TNNT2, MYH6,
and MYL7 was found, including modest elevation of the
nodal-associated transcription factor TBX3 and the pace-
maker channel HCN4, but MYL2 expression was reduced
(Figure 1H).
Characterizing the remaining non-CMs showed 4%
smooth muscle actin (SMA)-positive cells compared with
18% in controls (Figures 1I and 1J) and a substantial
drop in endothelial cell marker CD31 expression (Fig-
ure 1K). Together, this indicates that the EBIO-mediated
enrichment of CMs is accompanied by a loss of non-CM
lineages including smooth muscle and endothelial cells,
but also reduced overall CM counts.
EBIO-Dependent CM Enrichment and Cell Depletion
Is PSC Line, Protocol, and Species Independent
To investigate the universal validity of EBIO-mediated
CM enrichment, we tested an additional hES3 sub-
clone as well as an entirely independent hPSC line
by applying (1) a growth factor (GF)-directed differ-
entiation protocol in serum-supplemented mediumichment of CMs
nt-dependent EBIO enrichment (n = 3 independent experiments;
CM numbers (B) and relative CM contents at the endpoint of dif-
l.
EBIO-treated (right panel) cells stained for a-actinin, cTnT, and
ht panel; scale bar, 50 mm; inset: 43 magnification).
experiments of one to two replicates, six data points; mean ± SEM)
ent experiments; mean ± SEM).
4 (all n = 6 independent experiments; mean ± SEM).
(SMA) on day 20 (I; scale bars, 200 mm) and quantification thereof
ent experiments; mean ± SEM) and the pluripotency marker POU5F1
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Figure 2. EBIO-Mediated CM Enrichment Is Independent of Applied Cell Lines and Differentiation Protocols
(A) Schematic of the GF differentiation protocol.
(B–F) Endpoint analysis on day 17 comparing EBIO treatment with controls (DMSO). (B) Representative pictures depicting dissociated and
replated cells stained for cTnT and NKX2.5. Scale bars, 200 mm. (C and D) Quantification of cells stained for cTnT (C) and a-actinin (D) (n = 3
independent experiments of three replicates, nine data points; mean ± SEM). (E) Cell yields on day 17 revealed a 5-fold expansion in
controls (left bar) compared with a decrease in total cell counts and CMs (cTnT+ or a-actinin+ cells) in EBIO-treated conditions (n = 2
independent experiments; mean ± SEM). EBIO (1 mM) was supplemented from day 6 to day 14. (F) EBIO-triggered CM enrichment was
confirmed by qRT-PCR for MYH6 and MYL7 (MLC2a), but accompanied by reduction in MYL2 (MLC2v; all n = 2 independent experiments;
mean ± SEM).
(G) Schematic of the WNT protocol.
(H–J) Flow cytometric assessment on day 16 shows CM enrichment following EBIO treatment based on staining against a-actinin and pan-
MHC, but is accompanied by a drop in expression of ventricular b-MHC (n = 3 independent experiments of one to two replicates, four data
points). Cyclosporine A (CsA; 10 mM) was applied as additional control substance (n = 2; mean ± SEM).
(K) Total cell and cardiomyocyte yields per flask on day 16 (n = 3 independent experiments of one to two replicates for control and EBIO
[four data points]; n = 2 independent experiments for CsA; mean ± SEM).
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.(intermediate cardiogenic efficiency [Burridge et al.,
2011]) and (2) a small-molecule-based differentiation
strategy using WNT pathway modulators (WNT proto-
col, high cardiogenic efficiency [Kempf et al., 2014]),
respectively.308 Stem Cell Reports j Vol. 8 j 305–317 j February 14, 2017Using hCBiPSC2 cells in the GF protocol (Figure 2A),
1 mM EBIO resulted in CM enrichment of 76.4%–80.5%
CMs (cTnT and a-actinin), whereas 0.5 mM EBIO resulted
in modest CM enrichment of 33%–51% compared with
6%–9.5% CMs in controls (Figures 2B–2D and S2A).
Notably, only0.3 differentiated cells per inoculated hPSC
were harvested following 1 mM EBIO treatment compared
with 5 cells in controls (Figure 2E). qRT-PCR for MYH6,
MYL7, and MYL2 (Figure 2F) recapitulated expression pat-
terns observed in the bSF protocol (Figure 1H).
Applying 1 mM EBIO to the HES3-aMHCneo line in the
WNT protocol (Figure 2G) elevated the CM content from
60.2% ± 8.1% (controls) to 86.7% ± 1.5% for a-actinin
and from 50.0% ± 2.6% to 88.4% ± 0.95% for pan-cardiac
myosin heavy chain (MHC) staining (Figures 2H and 2I).
Notably, specific analysis with b-MHC, the MHC isoform
predominantly expressed in ventricular CMs (Gorza et al.,
1984), showed a significant decrease from 20.9% ± 4.1%
in controls to 9.2%± 2.4% in treated cells (Figure 2J). Again,
EBIO treatment was accompanied by70% overall cell loss
(Figure 2K).
Cyclosporine A (CsA) was previously reported to modu-
late CM induction at a cardiac progenitor stage for murine
and human PSCs (Cho et al., 2014; Fujiwara et al., 2011).
We thus included this compound as an additional control.
Interestingly, 10 mMCsA resulted in a substantial reduction
of the overall cell counts similar to EBIO (Figure 2K), but
without inducing significant CM enrichment and without
reduction of b-MHC expression (Figures 2H–2J), suggesting
distinct mechanisms between both substances.
Mouse ESC experiments equivalent to published proced-
ures (Kleger et al., 2010) confirmed CM enrichment from
3.74% ± 0.8% in controls to 71.1% ± 8.1% in response to
EBIO (Figures S2B–S2F). In line with our hPSC data, cell
counts showed a drastic drop in overall and CM-specific
numbers (Figure S2G) not reported for mouse PSCs in
previous studies (Kleger et al., 2010; Muller et al., 2012).
To rule out batch-dependent effects of the drug, we ob-
tained EBIO from two independent sources. High-perfor-
mance liquid chromatography revealed >99% substance
purity of three individual batches (Figure S2H), all of
which showed undistinguishable biological activity (data
not shown).
EBIO Treatment Results in Elevated Proportions of
CMs with Short AP Duration
Whole-cell patch-clamp recordings revealed hPSC-CMs
with ventricular-like, atrial-like, and nodal-like phenotype
(Figure 3A). EBIO treatment caused a significant reduction
of the overall AP duration (Figure 3B) by apparent deple-
tion of CMs with long APs (ventricular-like), resulting
in an enrichment of phenotypes with shorter APs (atrial-
like, nodal-like, and spike-like), which tallies with our
gene expression analyses. Kleger et al. (2010) reported an
enrichment of pacemaker cells for murine CMs. Here, we
tested this effect on humanPSC-CMs. Indeed, wemeasured
a number of bell-shaped APs in the EBIO-treated cells. At
first glance, such AP shapes could be assigned as nodal-like (Figure 3C, left traces) due to the low upstroke veloc-
ities, which is evoked by low expression of Nav1.5 sodium
channels in bona fide pacemaker cells (Maier et al., 2003).
However, spontaneously active CMs tested in our study dis-
played mean maximum diastolic potentials of 65 ± 3 mV
(n = 16), whereby most Nav1.5 channels are inactivated.
Therefore, we hyperpolarized respective cells tomore phys-
iological resting potentials around80mVand elicited APs
by intracellular stimulation (Figure 3C, right traces). Under
such conditions, most CMs produced APs with fast up-
stroke velocities (>30 mV/ms), considerable overshoot,
and a clear plateau for ventricular-like cells (Figure 3C, up-
per traces) or triangular shapes typical of atrial-like cells
(not shown). Only two CMs out of 56 EBIO-treated and
42 control cells tested (total 98 cells) maintained the bell-
shaped AP appearance with low upstroke velocity, proving
their nodal-like properties (Figure 3C, lower traces). Instead
of the hypothesized pacemaker enrichment we frequently
observed CMs with very short APs (AP duration at 50% of
amplitude [APD50] <20 ms) and fast upstroke velocities
(82 ± 14 mV/ms, n = 11) in the EBIO-treated group (Fig-
ure 3D), designated spike-like in this study. Figure 3E
summarizes the effect of EBIO on the distribution of CM
phenotypes, demonstrating a decreased amount of ventric-
ular-like cells and elevated proportions of CMs with short
AP duration (atrial-like and spike-like). Notably, CsA sup-
plementation tends to shift the subtype distribution in
the opposite direction, i.e., supporting survival of CMs
with long AP duration (Figures 3B and 3E), further suggest-
ing a distinct mode of action compared with EBIO.
To further substantiate the electrophysiological data,
we assessed gene expression patterns of established CM
subtype-specific markers by microarray analysis applying
cells derived by the WNT protocol (shown in Figures 2G–
2K). EBIO supplementation resulted in reduced expression
of ventricular markers MYL2, MYH7, IRX4, HEY2, and
GJA1 (Figure S3A), consistent with (1) reduced MLC2v
(MYL2) and b-MHC (MYH7) expression observed across
all three differentiation platforms, and (2) the reduced frac-
tion of CMs showing ventricular-like APs (Figure 3). In
contrast, atrial-specific markers including Kir3.1, Kv1.5,
and Cav1.3 (Devalla et al., 2015) were consistently upregu-
lated (Figure S3B), while pacemaker-specific marker re-
mained essentially unchanged (Figure S3C). Notably,
upregulation of Kv1.5 increases the ultra-rapid potassium
current (Kur) of atrial cardiomyocytes that tends to shorten
APs (Christophersen et al., 2013; Grant, 2009). Moreover,
our analysis unraveled an increased KCND3 and KCNA4
expression (Figure S3D), coding for Kv4.3 and Kv1.4 chan-
nels that define the plateau level of cardiac APs by transient
potassium currents (Ito) in atrial and ventricular cardio-
myocytes (Grant, 2009). It is tempting to speculate that
increased expression of these channels might explain theStem Cell Reports j Vol. 8 j 305–317 j February 14, 2017 309
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Figure 3. EBIO Treatment Alters CM Sub-
type Composition toward Shortened Ac-
tion Potentials
(A) AP recordings from control (left) and
EBIO-treated (right) hESC-derived CMs re-
vealed differentiation into ventricular-like
(upper panel), atrial-like (middle panel),
and presumptive nodal-like (lower panel)
cells.
(B) AP duration (APD50, elicited at a resting
potential of 80 mV) of control (n = 24)
and EBIO (n = 36) or CsA (n = 13 cells
from two independent differentiation ex-
periments) treated CMs. Means ± SEM are
indicated in the dot plot. ***p < 0.001; n.s.,
not significant.
(C) Representative patterns of spontaneous
and evoked (elicited at 80 mV) APs from
the same cell of a ventricular-like cell (upper
panel), atrial-like cell (middle panel), and
nodal-like cell (lower panel), respectively.
(D) Representative recording of a spike-like
CM with very short AP duration and fast
upstroke velocity (note the expanded time
scale in the right panel).
(E) CM subtype composition for control (n =
42), EBIO-treated (n = 56), and CsA-treated
conditions (n = 18; cells from four inde-
pendent differentiation experiments). Mi-
croarray analysis was conducted to confirm
CM subtype shift and is shown in Figure S3.occurrence of spike-like APs in EBIO-treated cells, when
early outward currents exceed the calcium influx and
impede the plateau generation in phase 2 of the AP.
Together, these data suggest that EBIO triggers enrich-
ment of cells with reduced AP duration, including higher
content of atrial-like, some nodal-like, and appearance
of spike-like identities, at the expense of ventricular-like
cardiomyocytes.
EBIO Treatment Does Not Induce Expression of
Mesodermal and Cardiac Lineage Markers but
Interferes with the Proliferation and Viability of
Undifferentiated hPSCs
Previous reports suggested that EBIO administration to hu-
man and mouse PSCs results in loss of pluripotency and310 Stem Cell Reports j Vol. 8 j 305–317 j February 14, 2017induction of mesodermal and the cardiac lineage (Kleger
et al., 2010; Muller et al., 2012). In our hands, decreased
expression of the pluripotency-associated markers OCT4
(POU5F1) and NANOG was indeed observed in hESCs
treated with 1 mM EBIO (Figures 4A and 4B). However,
mesodermal and cardiac markers (T, MESP1, MIXL1, ISL1,
and MYH6) showed lower or similar expression levels
compared with controls, whereas expression of SOX1 and
SOX17, markers of early ectoderm and endoderm forma-
tion, respectively, were slightly upregulated, but at very
low overall expression levels as expected for undifferenti-
ated hPSC cultures (Figures 4A and 4B).
Growth kinetics revealed significantly reduced cell
survival in response to EBIO compared with controls
after 72 hr (Figure 4C). A large proportion of ethidium
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homodimer 1 (EthD-1) intercalating cells (Figure 4D) and
the high rate of propidium iodide (PI)-positive cells (Fig-
ure 4E) underscored induction of cell death by 1 mM
EBIO. Interestingly, shifting hPSC cultures from normoxic
culture conditions (21% O2) to low oxygen conditions
(2.5% O2) for 48 hr induced proliferation arrest and
blocked the detrimental effect of EBIO in hESCs (Figure 4F)
and hiPSCs (Figure S4D), suggesting that less proliferative
cells are less susceptible to EBIO-mediated toxicity.
To test whether drug toxicity was restricted to highly pro-
liferative hPSCs, we analyzed growth kinetics of additional
human cell types. Foreskin fibroblasts and cord blood
endothelial cells showed a complete block of cell prolifera-
tion but no apparent reduction in cell viability. However,
highly proliferative HeLa cells mimicked the hPSC pattern
regarding loss of cell viability (Figures S4A–S4C), under-
scoring that 1 mM EBIO induces cell death predominantly
in highly proliferative cells.
SK4 Is Not Upregulated in Cardiac Progenitors during
Early Cardiac Differentiation
EBIO is thought to mediate its effect specifically through
positive modulation of SK channel activity (with SK4
being most sensitive to the drug) (Kleger et al., 2010). The
time dependency of EBIO treatment prompted us to
perform a detailed expression pattern analysis during the
first 8 days of differentiation in the bSF protocol. The
expression for cardiac differentiation markers resulted
in expected patterns (Graichen et al., 2008) such as T
and MESP1 expression peaking on days 2–3 followed byFigure 4. EBIO Does Not Induce Mesodermal Differentiation an
Mechanism
(A) Schematic outline of the supplementation procedure.
(B) qRT-PCR analysis for early differentiation markers shows no induc
iments of two replicates, four data points; mean ± SEM).
(C) Cell counts after 24–72 hr of treatment revealed decreased cel
mean ± SEM).
(D) Live (calcein, green) and dead (EthD-1, red) staining after 72 hr.
(E) Flow cytometric quantification of propidium iodide (PI+; dead) cel
data points; mean ± SEM).
(F) Culture of hPSCs under hypoxic conditions derogated the toxic
experiments of two replicates, four data points; mean ± SEM).
(G) Expression profile of SK1–4 (KCNN1–4) in the bSF differentiation
(H) Differentiating hESCs were treated on day 6 for 48 hr with 1 mM
cytometry (n = 4 independent experiments; mean ± SEM).
(I) Cell viability was assessed after 48 hr of EBIO treatment on day 8
dependent experiments; mean ± SEM).
(J and K) qPCR analysis of cells sorted for KDR+/PDGFRa+ and KDR/P
(n = 3) for cardiac progenitor markers (TBX3, n = 2; TBX5, GATA4, ISL1,
(L and M) Concomitant addition of clotrimazole (CLZ) does not bloc
(L; n = 3 for controls and 250 nM; n = 2 for 1,250 nM) and after treat
experiments; mean ± SEM).
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.
312 Stem Cell Reports j Vol. 8 j 305–317 j February 14, 2017upregulation of cardiac progenitor markers ISL1, TBX3,
GATA4, TBX5, MEF2C, and NKX2.5 on days 3–5, respec-
tively (Figure S4E). Regarding SK channel expression, we
found substantial upregulation of SK2 from days 5–6 on-
ward, whereas expression of other subtypes dropped or re-
mained unchanged but were notably at a >10-fold lower
expression level (Figure 4G).
We further explored this aspect via flow cytometry by
analyzing SK expression in a cardiac progenitor population
marked by platelet-derived growth factor receptor/kinase
insert domain receptor positivity (PDGFR+/KDR+) (Katt-
man et al., 2011). A significantly higher amount of
PDGFR+/KDR+ cells was observed after 48 hr of EBIO treat-
ment on day 8 of differentiation (Figure 4H). Viability
staining showed substantial EBIO-induced cell death (Fig-
ure 4I), suggesting that the increase in PDGFR+/KDR+ pop-
ulation was provoked by a loss of PDGFR/KDR cells. We
next analyzed SK channel expression in PDGFR+/KDR+-
sorted cells. As expected, cardiac progenitor markers
including TBX3, TBX5, and GATA4 (Figure 4J) were
elevated in PDGFR+/KDR+, whereas almost no differential
SK2 expression but notably a significantly lower expression
of SK4 was detected (Figure 4K).
SK Channel Blockers Do Not Reverse EBIO-Mediated
Effects
Aiming at specifically reversing the EBIO-mediated effects,
several established SK channel blockerswere supplemented
at relevant concentrations in parallel to EBIO including
clotrimazole (blocking SK4), apamin (blocking SK1–3),d Mediates Its Cell-Selective Effects via an SK4-Independent
tion of mesodermal markers after 72 hr (n = 2 independent exper-
l numbers in response to EBIO (n = 3 independent experiments;
Scale bars, 100 mm.
ls after 72 hr (n = 2 independent experiments of two replicates, four
effect of EBIO at all tested concentrations (n = 2 independent
(n = 3 independent experiments; mean ± SEM).
EBIO and analyzed for the expression of KDR+ and PDGFR+ by flow
by flow cytometry for live (calcein) and dead (PI) cells (n = 4 in-
DGFRa on day 6 of differentiation independent of EBIO addition
n = 3) and SK1–4 (n = 3; all independent experiments; mean ± SEM).
k EBIO-mediated cell depletion in hPSCs after 48 hr of incubation
ment for 10 days during differentiation (M; n = 3, all independent
and iberiotoxin (blocking large-conductance Ca2+-acti-
vated potassium channels). None of these drugs derogated
the EBIO-dependent cell depletion, either at the undiffer-
entiated hPSC state (Figures 4L and S4F) or during differen-
tiation (Figures 4M, S4G, and S4H). This suggests that
the anti-proliferative and pro-cytotoxic effects of EBIO are
independent of SK channel function.
Ultimately, we tested whether alternative positive SK
modulators could mimic EBIO-mediated effects during
hPSC differentiation. Interestingly, 15 mM CyPPA, a selec-
tive SK2/SK3 channel modulator (Hougaard et al., 2007),
showed a similar response (Figures S4I, S4K, and S4L). In
contrast, NS309, a highly potent EBIO analog (most potent
on SK4 activity, EC50 = 0.01 mM) (Strobaek et al., 2004),
resulted in neither CM enrichment nor apparent changes
in overall cell counts (Figures S4J–S4L), as further validated
in undifferentiated hPSCs (Figures S4M and S4N).
Together these data suggest that EBIO effects—prolifera-
tion arrest, cell depletion, CM enrichment, and CM
subtype shift—are mostly (or entirely) independent of
compounds’ established modulation of SK4 activity but
are likely mediated by other mechanisms.DISCUSSION
Previous studies suggested the induction of cardiomyo-
genic differentiation with increased yields of nodal-like
cells using 1 mM EBIO, a positive modulator of SK chan-
nel activity (SK4 EC50 30 mM; 10–20 times less potent
for SK1-3 EC50 600–1,000 mM [Pedarzani et al.,
2001]). Here, we investigated the EBIO-mediated effect
in four independent cardiac differentiation protocols,
i.e., three for human and one for mouse PSC lines,
with routine cardiac differentiation efficiencies ranging
from 10% to 60% of CM induction. In striking contrast
to previous reports, we could not attribute any meso-
derm-inductive effects to EBIO (Figure 4B). Instead,
EBIO induced significant cell loss accompanied by selec-
tive survival of CMs, ultimately leading to increased CM
purity of >70% independent of the applied differentia-
tion protocol (Figures 1 and 2). Likewise, we could
not confirm the increased fraction of CMs with nodal-
like APs, but observed an overall preponderance of
CMs with significantly shortened AP duration following
EBIO treatment (Figure 3).
During heart development, both conduction-system-
and working-myocardium-forming CMs are derived
from one common progenitor. Such primitive CM pro-
genitors are hallmarked by TBX3 expression, proliferate
slowly, soon become post-mitotic, and will mainly form
nodal-like cells (Bakker et al., 2010). In our differentiation
protocols applying hPSCs we showed that TBX3 as well asthe expression of other early cardiac progenitor markers
(TBX5, GATA4, and ISL1) was upregulated on days 4–6,
suggesting that primitive CM progenitors were formed
within this time window under our in vitro conditions,
representing a differentiation stage equivalent to early
heart tube formation in vivo (McCulley and Black,
2012). These cardiac progenitors with their primary
potential to form atrial cell types might be less sensitive
to EBIO, possibly due to their specific ion channel
expression pattern, early cell-cycle withdrawal, and/or
metabolic features, resulting in their selective survival
upon drug supplementation. In good agreement with
our data, continuous application of the drug not only
depleted most non-CM lineages but also interfered with
the differentiation and/or proliferation of later-forming
ventricular-like CMs, thereby inducing the observed CM
subtype shift. Since our differentiation protocols, without
drug administration, mainly yield ventricular-like cells
(Kempf et al., 2014), inhibition and/or depletion of ven-
tricular-like cell fates by EBIO may underlie the overall
reduction of CM yields and depletion of cells with pro-
longed APs.
We functionally screened spontaneously active CMs for
pacemaker properties, revealing that the majority of such
cells had ventricular- or atrial-like but not nodal-like prop-
erties, when APs were elicited from physiological resting
potentials (80 mV). Nav1.5 is the main sodium channel
specifying atrial and ventricular cardiomyocytes; this chan-
nel is semi-inactivated at 82 mV and nearly completely
inactivated at 60 mV (Lei et al., 2004; Maier et al.,
2003). Therefore, upstroke velocities are expected to be
low whenever the membrane potential is shifted toward
less negative values, which typically reflects conditions of
immature atrial- and ventricular-like phenotypes at early
stages of differentiation (Satin et al., 2004). In contrast,
pacemaker cells of the sinoatrial node express Nav1.1.
This channel activates and inactivates at approximately
25 mV more positive membrane potentials, and can
therefore participate in the upstroke of pacemaker cells
despite the slow diastolic depolarization of the heart (Lei
et al., 2004). However, the Nav1.1 channel does not induce
high upstroke velocities, since the upstroke of nodal cells is
mainly dependent on voltage-activated calcium channels
(Dan et al., 2014). Accordingly, our functional test is well
suited to distinguish between APs representing immature
atrial- or ventricular-like cardiomyocytes from bona fide
pacemaker cells. Initiating measurements from 80 mV,
themajority of CMs displayed APs with fast upstroke veloc-
ities whereby a broad range of AP duration patterns was
observed. Recent reports indicate that the cell density as
well as the cell source and/or culture conditions may
influence AP shape variability and, subsequently, mean
AP duration (Du et al., 2015; Hortigon-Vinagre et al.,Stem Cell Reports j Vol. 8 j 305–317 j February 14, 2017 313
2016). To account for these issues, we applied equivalent
culture conditions for drug treatment and controls and
by ensuring harmonized conditions for patch-clamp anal-
ysis. This allowed unequivocal demonstration that EBIO
treatment results in CM populations with significantly
shorter APs. We interpret these results as enrichment of
CMs with relatively short plateau phases (atrial-like) or
even abolished plateaus (spike-like) resulting from ventric-
ular-like phenotype reduction.
According to previous work, EBIO mediates its effects
on mouse and human PSCs by compounds’ established
SK4-specific activity (Kleger and Liebau, 2011; Kleger
et al., 2010). This is a critical notion, since the effect of
EBIO is strictly dependent on drug concentrations above
500 mM in our study, which is actually in the range re-
ported for EBIOs’ EC50 for SK1–3. In line with this, we
have observed a very low expression of SK4 in pluripo-
tent cells, tallying with the lack of SK-specific currents
demonstrated in hPSCs (Jiang et al., 2010). Moreover,
we demonstrated further downregulation of SK4 during
differentiation and more specifically in cardiac progeni-
tors (Figures 4G and 4J). Furthermore, NS309, a >1,000-
fold more potent EBIO analog (EC50 SK4 0.01 mM
[Strobaek et al., 2004]), did not mimic EBIO-mediated
effects. In contrast, high concentrations of CyPPA, (i.e.,
15 mM) an SK2/SK3-specific modulator, resulted in
similar effects compared with EBIO. However, since the
application of established SK blockers did not disrupt
compound-dependent cell loss and CMs enrichment, a
mechanism(s) mediated independently of SK channel
modulation seems likely.
It is worth highlighting that a previously described
method for CM purification by metabolic selection (To-
hyama et al., 2013) results in a similar loss of 50%–90%
of vital CM counts (Fuerstenau-Sharp et al., 2015). It is
thus tempting to speculate that the EBIO effect is medi-
ated through a metabolic mechanism, which is in agree-
ment with the loss of cell sensitivity in less proliferative
cells, i.e., irradiated fibroblasts and hPSCs switched to
low oxygen conditions (Figures S4A–S4D, S4F, S4L, and
S4M). However, more in-depth analysis beyond the scope
of this study is required to further investigate these
mechanisms.
In conclusion, we report pharmacological means for
the efficient enrichment of CMs from human PSCs
including a shift toward cells with shorter AP duration.
Mechanistically, a yet unappreciated lineage selectivity of
pharmacological SK modulators is described, which is
likely independent of compounds’ known modulation of
SK channel activity. The resulting level of CM purity and
the sensitivity of undifferentiated and proliferative hPSCs
to cytotoxic drug effects are potentially valuable for the
envisioned therapeutic applications of hPSC-derived CMs.314 Stem Cell Reports j Vol. 8 j 305–317 j February 14, 2017EXPERIMENTAL PROCEDURES
Human ESC and iPSC Culture
The human ESC line HES3 (ES Cell International) and the human
iPSC clone hCBiPS2 (Haase et al., 2009) were cultured in 6-well
plates (Nunc) on irradiated human foreskin fibroblasts (hFFs)
(ATCC) or murine embryonic fibroblasts, respectively, in KO-SR
medium consisting of KnockOut DMEM (Gibco) supplemented
with 20% KnockOut Serum Replacement (Gibco), 1% non-essen-
tial amino acids (Gibco), 1 mmol/L L-glutamine (Gibco), and
0.1 mmol/L b-mercaptoethanol (Gibco). Basic fibroblast growth
factor (bFGF) (Chen et al., 2012) was added, 50 ng/mL for HES3
and 10ng/mL for hCBiPS2 cultivation. For passaging, cells were de-
tached every 4–7 days using 0.2% collagenase IV (Gibco). Culture
medium was changed every 2–3 days. For feeder-free cultivation,
HES-3 cells were cultivated on Matrigel (BD Bioscience) in KO-SR
mediumwith 100ng/mL bFGF. For single culture, cells were seeded
at 2.5 3 104 cells/cm2 in the presence of 10 mM Rho-Kinase inhib-
itor (RI) Y-27632 (Palecek et al., 2011). Mediumwas changed daily.
For live/dead staining, plated cells were incubated for 30 min with
1 mM calcein and 4 mMethidium homodimer 1 (Life Technologies)
at 37C.
bSF Protocol: Differentiation in Chemically Defined
Conditions
Cells were mechanically detached from the conventional 6-well
plate culture (Nunc) using a cell scraper and transferred to 6-well
suspension plates (Greiner) in a well-per-well scheme for EB-based
differentiation in basic serum-free (bSF) medium (Kempf et al.,
2011; Xu et al., 2008) consisting of DMEM (Gibco) supplemented
with 1%non-essential amino acids (Gibco), 2mmol/L L-glutamine
(Gibco), 0.1 mmol/L b-mercaptoethanol (Gibco), 5.6 mg/L trans-
ferrin (Sigma-Aldrich), and 37.2 mg/L sodium selenite (Sigma-
Aldrich). bSF medium was supplemented with 5 mM SB203580
(Graichen et al., 2008), a p38 MAPK inhibitor, from day 0 to
day 6. The compounds 1-ethyl-2-benzimidazolinone (EBIO; 1 M
stock solution; Tocris Bioscience or Institute of Organic Chemistry
at Hannover University), CyPPA (15 mM stock solution, Tocris),
and NS309 (3 mM stock solution, Tocris) were added at respective
concentrations and timing as described in Results. DMSO (Sigma-
Aldrich), the solvent of EBIO, CyPPA, and NS309, was applied in
respective amounts in controls. Apamin was diluted in sterile
H2O (Tocris, 0.1 mM stock solution). Medium was changed every
2–3 days. Before EB dissociation for endpoint analysis, cells were
cultured for 24 hr in bSF medium.
GF Protocol: Differentiation Based on Growth Factors
The iPSC line hCBiPS2 (Haase et al., 2009) was cultured on Gel-
trex (Gibco) in a monolayer with feeder-conditioned medium
for at least four passages (Burridge et al., 2011). EB-based differen-
tiation was induced for 2 days cultivating 5,000 cell/V96 in RPMI
medium (Gibco) containing 25 ng/mL BMP4 (R&D Systems),
10 ng/mL FGF2, insulin (Sigma-Aldrich), and polyvinyl alcohol
(Sigma-Aldrich). After 2 days in medium supplemented with fetal
calf serum, EBs were transferred to U96 plates in RPMI medium
containing insulin (Sigma-Aldrich) on day 4. EBIO was added as
indicated.
WNT Protocol: Differentiation Based on Small
Molecules
The HES3-aMHCneo line (Schwanke et al., 2014) was differenti-
ated as described previously (Kempf et al., 2014). In brief, cells
were cultured under feeder-free conditions on Geltrex-coated
flasks in mTeSR1 (STEMCELL Technologies) for at least four
passages. Aggregates were generated from single-cell suspen-
sions at 0.33 3 105 cells/mL in mTeSR1 supplemented with
10 mM Y-27632 for 4 days. Differentiation was performed in
agitated (orbital shaker at 75 rpm; Infors-HT) Erlenmeyer flasks
(125 mL, VWR International) in 20-mL scale using RPMI supple-
mented with B27 without insulin (Life Technologies). For induc-
tion of differentiation, 7.5 mM CHIR99021 (Institute of Organic
Chemistry, Leibnitz University Hannover) was supplemented
during the first 24 hr, followed by 5 mM IWP2 for 48 hr (Tocris).
Medium was replaced every second day. The cells were main-
tained in RPMI supplemented with B27 (Life Technologies)
from day 6 onward.Mouse ESC Culture and Differentiation
The murine ESC line OG2 was cultured on irradiated mouse
fibroblast or feeder-free as previously described (Mauritz et al.,
2008). For differentiation, cells were detached from 6-well
plates (Nunc) and dissociated with 0.025% trypsin (Sigma).
EBs were formed with differentiation medium consisting of
Iscove’s modified Dulbecco’s medium (Gibco) supplemented
with 15% fetal calf serum, 1% non-essential amino acids (Gibco),
0.2 mmol/L L-glutamine (Gibco), and 0.1 mmol/L b-mercaptoe-
thanol (Gibco), in hanging drops (600 cells/drop) for the first
3 days of differentiation. On day 3 EBs were transferred into sus-
pension culture dishes (Nunc) and subsequently plated onto
0.1% gelatin-coated 6-well plates (Nunc, 10 EBs per 6 wells).
Further differentiation was performed in 1 mM EBIO supple-
mented from day 1 to day 15 (Figure S3) as previously described
(Kleger et al., 2010).Statistical Analysis
Error bars representmean ± SEMunless otherwise noted. Statistical
significance was calculated using an unpaired Student’s t test.
Multiplicity of testing was accounted for by one-way ANOVA fol-
lowed by Bonferroni’s post test. Significance is shown in the figures
as *p < 0.05, **p < 0.01, and ***p < 0.001.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, two tables, and three movies and can
be found with this article online at http://dx.doi.org/10.1016/j.
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